Patents by Inventor Benjamin R. TAFT

Benjamin R. TAFT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FUSED TRICYCLIC PYRIDAZINONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS
    Publication number: 20250011334
    Abstract: The invention provides compounds of Formula (1): as further described herein, as well as pharmaceutical compositions comprising such compounds, and methods to use the compounds and pharmaceutical compositions for treatment of certain viral disorders, including influenza.
    Type: Application
    Filed: June 13, 2024
    Publication date: January 9, 2025
    Inventors: Rama JAIN, Dennis Christofer KOESTER, James R. MANNING, Vanessa MARX, Daniel POON, James Clifford SUTTON, Benjamin R. TAFT, Lifeng WAN, Aregahegn YIFRU, Qian ZHAO
  • Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections
    Patent number: 11912715
    Abstract: The invention provides compounds of Formula (I): as further described herein, as well as pharmaceutical compositions comprising such compounds, and methods to use the compounds and pharmaceutical compositions for treatment of certain viral disorders, including influenza.
    Type: Grant
    Filed: July 13, 2021
    Date of Patent: February 27, 2024
    Assignee: Novartis AG
    Inventors: Rama Jain, Dennis Christofer Koester, James R. Manning, Vanessa Marx, Daniel Poon, James Clifford Sutton, Benjamin R. Taft, Lifeng Wan, Aregahegn Yifru, Qian Zhao
  • Fused Tricyclic Pyridazinone Compounds Useful to Treat Orthomyxovirus Infections
    Publication number: 20220041610
    Abstract: The invention provides compounds of Formula (I): as further described herein, as well as pharmaceutical compositions comprising such compounds, and methods to use the compounds and pharmaceutical compositions for treatment of certain viral disorders, including influenza.
    Type: Application
    Filed: July 13, 2021
    Publication date: February 10, 2022
    Inventors: Rama JAIN, Dennis Christofer KOESTER, James R. MANNING, Vanessa MARX, Daniel POON, James Clifford SUTTON, Benjamin R. TAFT, Lifeng WAN, Aregahegn YIFRU, Qian ZHAO
  • Biaryl amide compounds as kinase inhibitors
    Patent number: 10709712
    Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: July 14, 2020
    Assignee: NOVARTIS AG
    Inventors: Robert John Aversa, Paul Andrew Barsanti, Matthew T. Burger, Michael Patrick Dillon, Alan Dipesa, Cheng Hu, Yan Lou, Gisele A. Nishiguchi, Yue Pan, Valery Rostislavovich Polyakov, Savithri Ramurthy, Alice C. Rico, Lina Quattrocchio Setti, Aaron Smith, Sharadha Subramanian, Benjamin R. Taft, Huw Roland Tanner, Lifeng Wan, Naeem Yusuff
  • Compounds and compositions as kinase inhibitors
    Patent number: 10392404
    Abstract: The present invention provides compounds of Formula (I) and (II) as described herein, and salts thereof and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: August 27, 2019
    Assignee: Novartis AG
    Inventors: Paul Andrew Barsanti, Matthew T. Burger, Yan Lou, Gisele A. Nishiguchi, Valery Rostislavovich Polyakov, Savithri Ramurthy, Sharadha Subramanian, Benjamin R. Taft, Huw Rowland Tanner, Lifeng Wan
  • BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20190175606
    Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
    Type: Application
    Filed: February 12, 2019
    Publication date: June 13, 2019
    Inventors: Robert John AVERSA, Paul Andrew BARSANTI, Matthew T. BURGER, Michael Patrick DILLON, Alan DIPESA, Cheng HU, Yan LOU, Gisele A. NISHIGUCHI, Yue PAN, Valery Rostislavovich POLYAKOV, Savithri RAMURTHY, Alice C. RICO, Lina Quattrocchio SETTI, Aaron SMITH, Sharadha SUBRAMANIAN, Benjamin R. TAFT, Huw Roland TANNER, Lifeng WAN, Naeem YUSUFF
  • Biaryl amide compounds as kinase inhibitors
    Patent number: 10245267
    Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: April 2, 2019
    Assignee: Novartis AG
    Inventors: Robert John Aversa, Paul Andrew Barsanti, Matthew T. Burger, Michael Patrick Dillon, Alan Dipesa, Cheng Hu, Yan Lou, Gisele A. Nishiguchi, Yue Pan, Valery Rostislavovich Polyakov, Savithri Ramurthy, Alice C. Rico, Lina Quattrocchio Setti, Aaron Smith, Sharadha Subramanian, Benjamin R. Taft, Huw Roland Tanner, Lifeng Wan, Naeem Yusuff
  • Compounds and compositions as RAF kinase inhibitors
    Patent number: 10167279
    Abstract: The present invention provides compounds of Formula (I) and (II) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: January 1, 2019
    Assignee: Novartis AG
    Inventors: Robert John Aversa, Matthew T. Burger, Michael Patrick Dillon, Thomas A. Dineen, Jr., Yan Lou, Gisele A. Nishiguchi, Savithri Ramurthy, Alice C. Rico, Vivek Rauniyar, Martin Sendzik, Sharadha Subramanian, Lina Quattrocchio Setti, Benjamin R. Taft, Huw Rowland Tanner, Lifeng Wan
  • Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections
    Patent number: 10160764
    Abstract: The invention provides compounds of Formula (I): as further described herein, as well as pharmaceutical compositions comprising such compounds, and methods to use the compounds and pharmaceutical compositions for treatment of certain viral disorders, including influenza.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: December 25, 2018
    Assignee: Novartis AG
    Inventors: Rama Jain, Dennis Christofer Koester, James R. Manning, Vanessa Marx, Daniel Poon, James Clifford Sutton, Benjamin R. Taft, Lifeng Wan, Aregahegn Yifru, Qian Zhao
  • COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS
    Publication number: 20180170917
    Abstract: The present invention provides compounds of Formula (I) and (II) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
    Type: Application
    Filed: September 11, 2015
    Publication date: June 21, 2018
    Inventors: Robert John AVERSA, Matthew T. BURGER, Michael Patrick DILLON, Thomas A. DINEEN, Jr., Yan LOU, Gisele A. NISHIGUCHI, Savithri RAMURTHY, Alice C. RICO, Vivek RAUNIYAR, Martin SENDZIK, Sharadha SUBRAMANIAN, Lina Quattrocchio SETTI, Benjamin R. TAFT, Huw Rowland TANNER, Lifeng WAN
  • FUSED TRICYCLIC PYRIDAZINONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS
    Publication number: 20180057501
    Abstract: The invention provides compounds of Formula (I): as further described herein, as well as pharmaceutical compositions comprising such compounds, and methods to use the compounds and pharmaceutical compositions for treatment of certain viral disorders, including influenza.
    Type: Application
    Filed: August 25, 2017
    Publication date: March 1, 2018
    Inventors: Rama JAIN, Dennis Christofer KOESTER, James R. MANNING, Vanessa MARX, Daniel POON, James Clifford SUTTON, Benjamin R. TAFT, Lifeng WAN, Aregahegn YIFRU, Qian ZHAO
  • Compounds and compositions as kinase inhibitors
    Patent number: 9809610
    Abstract: The present invention provides a compound of Formula I: wherein X, Y, Z, R1 and R2 are as described herein, and salts thereof and therapeutic uses of these compounds for treatment of disorders associated with RAF kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
    Type: Grant
    Filed: January 4, 2017
    Date of Patent: November 7, 2017
    Assignee: Novartis AG
    Inventors: Matthew T. Burger, Savithri Ramurthy, Benjamin R. Taft
  • COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS
    Publication number: 20170260200
    Abstract: The present invention provides compounds of Formula (I) and (II) as described herein, and salts thereof and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
    Type: Application
    Filed: September 11, 2015
    Publication date: September 14, 2017
    Inventors: Paul Andrew BARSANTI, Matthew T. BURGER, Yan LOU, Gisele A. NISHIGUCHI, Valery Rostislavovich POLYAKOV, Savithri RAMURTHY, Sharadha SUBRAMANIAN, Benjamin R. TAFT, Huw Rowland TANNER, Lifeng WAN
  • BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20170260207
    Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
    Type: Application
    Filed: May 22, 2017
    Publication date: September 14, 2017
    Inventors: Robert John AVERSA, Paul Andrew BARSANTI, Matthew T. BURGER, Michael Patrick DILLON, Alan DIPESA, Cheng HU, Yan LOU, Gisele A. NISHIGUCHI, Yue PAN, Valery Rostislavovich POLYAKOV, Savithri RAMURTHY, Alice C. RICO, Lina Quattrocchio SETTI, Aaron SMITH, Sharadha SUBRAMANIAN, Benjamin R. TAFT, Huw Roland TANNER, Lifeng WAN, Naeem YUSUFF
  • COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS
    Publication number: 20170114083
    Abstract: The present invention provides a compound of Formula I: wherein X, Y, Z, R1 and R2 are as described herein, and salts thereof and therapeutic uses of these compounds for treatment of disorders associated with RAF kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
    Type: Application
    Filed: January 4, 2017
    Publication date: April 27, 2017
    Applicant: NOVARTIS AG
    Inventors: Matthew T. BURGER, Savithri RAMURTHY, Benjamin R. TAFT
  • Compounds and compositions as kinase inhibitors
    Patent number: 9573969
    Abstract: The present invention provides a compound of Formula I: wherein X, Y, Z, R1 and R2 are as described herein, and salts thereof and therapeutic uses of these compounds for treatment of disorders associated with RAF kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: February 21, 2017
    Assignee: NOVARTIS AG
    Inventors: Matthew T. Burger, Savithri Ramurthy, Benjamin R. Taft
  • COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS
    Publication number: 20160075727
    Abstract: The present invention provides a compound of Formula I: wherein X, Y, Z, R1 and R2 are as described herein, and salts thereof and therapeutic uses of these compounds for treatment of disorders associated with RAF kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
    Type: Application
    Filed: September 11, 2015
    Publication date: March 17, 2016
    Applicant: Novartis AG
    Inventors: Matthew T. Burger, Savithri RAMURTHY, Benjamin R. TAFT